Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

被引：21

作者：

Kennedy, Oliver J. ^{[1
]}

Kicinski, Michal ^{[2
]}

Valpione, Sara ^{[3
]}

Gandini, Sara ^{[4
]}

Suciu, Stefan ^{[2
]}

Blank, Christian U. ^{[5
]}

Long, Georgina, V ^{[6
,7
]}

Atkinson, Victoria G. ^{[8
]}

Dalle, Stephane ^{[9
]}

Haydon, Andrew M. ^{[10
]}

Meshcheryakov, Andrey ^{[11
]}

Khattak, Adnan ^{[12
,13
]}

Carlino, Matteo S. ^{[14
,15
]}

Sandhu, Shahneen ^{[16
]}

Larkin, James ^{[17
]}

Puig, Susana ^{[18
,19
]}

Ascierto, Paolo A. ^{[20
]}

Rutkowski, Piotr ^{[21
]}

Schadendorf, Dirk ^{[22
]}

Koornstra, Rutger ^{[23
]}

Hernandez-Aya, Leonel ^{[24
]}

Di Giacomo, Anna M. ^{[25
]}

van den Eertwegh, Alfonsus J. M. ^{[26
]}

Grob, Jean-Jacques ^{[27
]}

Gutzmer, Ralf ^{[28
,29
]}

Jamal, Rahima ^{[30
]}

van Akkooi, Alexander C. J. ^{[5
]}

Robert, Caroline ^{[31
]}

Eggermont, Alexander M. M. ^{[32
,33
,34
]}

Lorigan, Paul ^{[35
,36
]}

Mandala, Mario ^{[37
]}

机构：

[1] Univ Manchester, Oxford Rd, Manchester M13 9PL, Lancs, England

[2] EORTC Headquarters, Brussels, Belgium

[3] Manchester & Christie NHS Fdn Trust, Canc Res UK Manchester Inst, Manchester, Lancs, England

[4] IRCCS, Mol & Pharmaco Epidemiol Unit, European Inst Oncol, Milan, Italy

[5] Netherlands Canc Inst Antoni van Leeuwenhoek, Amsterdam, Netherlands

[6] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[7] Mater & Royal North Shore Hosp, Sydney, NSW, Australia

[8] Princess Alexandra Hosp, Brisbane, Qld, Australia

[9] Hosp Civils Lyon, Canc Inst, Lyon, France

[10] Alfred Hosp, Melbourne, Vic, Australia

[11] NN Blokhin Canc Res Ctr, Moscow, Russia

[12] Fiona Stanley Hosp, Perth, WA, Australia

[13] Edith Cowan Univ, Perth, WA, Australia

[14] Westmead & Blacktown Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

[15] Univ Sydney, Sydney, NSW, Australia

[16] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[17] Royal Marsden Hosp, London, England

[18] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain

[19] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Barcelona, Spain

[20] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[21] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[22] Univ Hosp Essen, Essen & German Canc Consortium, Heidelberg, Germany

[23] Radboud Univ Nijmegen, Med Ctr Nijmegen, Nijmegen, Netherlands

[24] Washington Univ, Sch Med, St Louis, MO USA

[25] Univ Hosp Siena, Ctr Immunooncol, Siena, Italy

[26] Univ Amsterdam, Med Ctr, Locat VUMC, Amsterdam, Netherlands

[27] Aix Marseille Univ, Hop Timone, Marseille, France

[28] Hannover Med Sch, Skin Canc Ctr, Hannover, Germany

[29] Ruhr Univ Bochum, Johannes Wesling Klinikum Minden, Dept Dermatol, Minden, Germany

[30] Ctr Hosp Univ Montreal CHUM, Ctr Rech Chum, Montreal, PQ, Canada

[31] Gustave Roussy & Paris Saclay Univ, Villejuif, France

[32] Comprehens Canc Ctr Munich, Munich, Germany

[33] Princess Maxima Ctr, Utrecht, Netherlands

[34] Univ Med Ctr Utrecht, Utrecht, Netherlands

[35] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[36] Christie NHS Fdn Trust, Manchester, Lancs, England

[37] Univ Perugia, Santa Maria Misericordia Hosp, Perugia, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 165卷

关键词：

Melanoma; Immunotherapy; Beta-blockers; Immunomodulation; Adrenergic beta-antagonists; METASTATIC MELANOMA; MALIGNANT-MELANOMA; SURVIVAL; RECURRENCE; OUTCOMES;

D O I：

10.1016/j.ejca.2022.01.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: fi-adrenergic receptors are upregulated in melanoma cells and contribute to an immunosuppressive, pro-tumorigenic microenvironment. This study investigated the prognostic and predictive value of fi-adrenoreceptor blockade by fi-blockers in the EORTC1325/KEYNOTE-054 randomised controlled trial. Methods: Patients with resected stage IIIA, IIIB or IIIC melanoma and regional lymphadenectomy received 200 mg of adjuvant pembrolizumab (n = 514) or placebo (n = 505) every three weeks for one year or until recurrence or unacceptable toxicity. At a median follow-up of 3 years, pembrolizumab prolonged recurrence-free survival (RFS) compared to placebo (hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.47-0.68). fi-blocker use was defined as oral administration of any fi-blocker within 30 days of randomisation. A multivariable Cox proportional hazard model was used to estimate the HR for the association between the use of fi-blockers and RFS. Results: Ninety-nine (10%) of 1019 randomised patients used fi-blockers at baseline. fi- blockers had no independent prognostic effect on RFS: HR 0.96 (95% CI 0.70-1.31). The HRs of RFS associated with fi-blocker use were 0.67 (95% CI 0.38-1.19) in the pembrolizumab arm and 1.15 (95% CI 0.80-1.66) in the placebo arm. The HR of RFS associated with pembrolizumab compared to placebo was 0.34 (95% CI 0.18-0.65) among fi-blocker users and 0.59 (95% CI 0.48-0.71) among those not using fi-blockers. Conclusions: This study suggests no prognostic effect of fi-blockers in resected high-risk stage III melanoma. However, fi-blockers may predict improved efficacy of adjuvant pembrolizumab treatment. The combination of immunotherapy with fi-blockers merits further investigation. This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-00494437. (c)& nbsp;& nbsp;& nbsp;2022 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). <comment>Superscript/Subscript Available</comment

引用

页码：97 / 112

页数：16

共 50 条

[1] Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
Eggermont, Alexander M. M.
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew
Lichinitser, Mikhail
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Di Giacomo, Anna Maria
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
Lupinacci, Robert
Krepler, Clemens
Ibrahim, Nageatte
Kicinski, Michal
Marreaud, Sandrine
van Akkooi, Alexander C.
Suciu, Stefan
Robert, Caroline
[J]. EUROPEAN JOURNAL OF CANCER, 2019, 116 : 148 - 157
[2] Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma*
Kennedy, Oliver John
Glassee, Nina
Kicinski, Michal
Blank, Christian U.
V. Long, Georgina
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Boers-Sonderen, Marye
Giacomo, Anna Maria Di
Eertwegh, Alfonsus J. M. van den
Grob, Jean -Jacques
Gutzmer, Ralf
Jamal, Rahima
Akkooi, Alexander C. J. van
Gandini, Sara
Buhrer, Emanuel
Suciu, Stefan
Robert, Caroline
Eggermont, Alexander M. M.
Mandala, Mario
Lorigan, Paul
Valpione, Sara
[J]. EUROPEAN JOURNAL OF CANCER, 2024, 201
[3] Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma
Kennedy, Oliver John
Kicinski, Michal
Valpione, Sara
Gandini, Sara
Suciu, Stefan
Blank, Christian U.
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Boers-Sonderen, Marye
Di Giacomo, Anna Maria
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
van Akkooi, Alexander C. J.
Robert, Caroline
Eggermont, Alexander M. M.
Lorigan, Paul
Mandala, Mario
[J]. EUROPEAN JOURNAL OF CANCER, 2023, 189
[4] EORTC 1325-MG/KEYNOTE-054 phase 3 trial of pembrolizumab versus placebo for completely resected high-risk stage III melanoma: pembrolizumab crossover and rechallenge following recurrence
Atkinson, Victoria
Eggermont, Alexander M. M.
Meshcheryakov, Andrey
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Barrow, Catherine
Di Giacomo, Anna Maria
Fisher, Rosalie
Sandhu, Shahneen
Kudchadkar, Ragini
Ortiz Romero, Pablo Luis
Svane, Inge Marie
van Akkooi, Alexander
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 161 - 161
[5] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Eggermont, Alexander M. M.
Meshcheryakov, Andrey
Atkinson, Victoria
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Barrow, Catherine
Di Giacomo, Anna Maria
Fisher, Rosalie
Sandhu, Shahneen
Kudchadkar, Ragini
Romero, Pablo Luis Ortiz
Svane, Inge Marie
Larkin, James
Puig, Susana
Hersey, Peter
Quaglino, Pietro
Queirolo, Paola
Stroyakovskiy, Daniil
Bastholt, Lars
Mohr, Peter
Hernberg, Micaela
Chiarion-Sileni, Vanna
Strother, Matthew
Hauschild, Axel
Yamazaki, Naoya
van Akkooi, Alexander Cj
Lorigan, Paul
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
[J]. EUROPEAN JOURNAL OF CANCER, 2021, 158 : 156 - 168
[6] Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Eggermont, Alexander M. M.
Kicinski, Michal
Blank, Christian U.
Mandala, Mario
V. Long, Georgina
Atkinson, Victoria
Dalle, Stephane
Haydon, Andrew
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Boers-Sonderen, Marye
Di Giacomo, Anna Maria
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
van Akkooi, Alexander C. J.
Lorigan, Paul
Grebennik, Dmitri
Kreplere, Clemens
Marreaud, Sandrine
Suciu, Stefan
Robert, Caroline
[J]. EUROPEAN JOURNAL OF CANCER, 2024, 211
[7] Prognostic and predictive value of an immune-related adverse event among stage III melanoma patients included in the EORTC 1325/KEYNOTE-054 pembrolizumab versus placebo trial.
Eggermont, Alexander M. M.
Kicinski, Michal
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Atkinson, Victoria
Dalle, Stephane
Haydon, Andrew Mark
Lichinitser, Mikhail
Khattak, Muhammad
Carlino, Matteo S.
Sandhu, Shahneen Kaur
Puig, Susana
Ascierto, Paolo Antonio
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Van Akkooi, Alexander Christopher Jonathan
Robert, Caroline
Suciu, Stefan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Eggermont, A. M. M.
Kicinski, M.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A. M.
Meshcheryakov, A.
Khattak, A.
Carlino, M. S.
Sandhu, S. K.
Sarda, S. S. Puig
Ascierto, P. A.
Lorigan, P.
Grebennik, D.
Ibrahim, N.
Marreaud, S. I.
Suciu, S.
Robert, C.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S912 - S913
[9] Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma
Khattak, A.
Robert, C.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V.
Dalle, S.
Haydon, A.
Lichinitser, M.
Carlino, M. S.
Sandhu, S.
Larkin, J.
Puig, S.
Ascierto, P. A.
Rutkowski, P.
Schadendorf, D.
Lorigan, P.
Ibrahim, N.
Suciu, S.
Eggermont, A. M. M.
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 48 - 48
[10] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
Eggermont, Alexander M.
Meshcheryakov, Andrey
Atkinson, Victoria
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Barrow, Catherine
Di Giacomo, Anna Maria
Stephens, Rosalie
Sandhu, Shahneen Kaur
Kudchadkar, Ragini Reiney
Ortiz-Romero, Pablo L.
Svane, Inge Marie
Van Akkooi, Alexander Christopher Jonathan
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →